Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,126 people get FOLD articles and Market Currents by email alert.
Get email alerts on FOLD »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Amicus Therapeutics: Amigal Drug Shows PromiseZacks Investment Research • Tue, Jul 7, 2009
-
-
-
-
-
-
-
-
-
-
-
-
These 5 Insider Favorites Are Trading At Big Discounts To Target PriceKapitall • Tue, Nov 13, 2012
-
-
-
-
-
-
-
-
-
Amicus' CEO Discusses Q3 2012 Results - Earnings Call TranscriptTue, Nov 6, 2012
-
Amicus Therapeutics Agreement with GSK - Call TranscriptSun, Oct 31, 2010
-
Amicus Therapeutics, Inc. Q2 2010 Earnings Call TranscriptThu, Aug 5, 2010
-
Amicus Therapeutics, Inc. Q1 2010 Earnings Call TranscriptFri, May 7, 2010
-
Amicus Therapeutics, Inc. Q4 2008 Earnings Call TranscriptWed, Feb 11, 2009
-
Amicus Therapeutics, Inc. Q3 2008 Earnings Call TranscriptThu, Nov 20, 2008
-
Amicus Therapeutics, Inc. Q2 2008 Earnings Call TranscriptTue, Sep 2, 2008
-
Amicus Therapeutics Inc. Q1 2008 Earnings Call TranscriptTue, May 13, 2008
-
GlobeNewswire (May 30, 2013)
-
GlobeNewswire (May 14, 2013)
-
GlobeNewswire (May 9, 2013)
-
GlobeNewswire (May 2, 2013)
-
GlobeNewswire (Apr 24, 2013)
-
GlobeNewswire (Mar 12, 2013)
-
GlobeNewswire (Mar 7, 2013)
-
GlobeNewswire (Mar 4, 2013)
-
GlobeNewswire (Feb 27, 2013)
-
GlobeNewswire (Feb 15, 2013)
-
GlobeNewswire (Feb 14, 2013)
-
Amicus Therapeutics Announces Posters and Presentations at Lysosomal Disease Network WORLD SymposiumGlobeNewswire (Feb 7, 2013)
-
GlobeNewswire (Jan 7, 2013)
-
at MarketWatch.com (Jan 4, 2013)
-
GlobeNewswire (Jan 2, 2013)
-
at MarketWatch.com (Dec 20, 2012)
FOLD vs. ETF Alternatives
Company Description
We are a biopharmaceutical company focused on the discovery, development and commercialization of orally-administered, small molecule drugs known as pharmacological chaperones. Pharmacological chaperones are a novel, first-in-class approach to treating a broad range of diseases including... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, June 17, 4:24 PM Amicus Therapeutics (FOLD -20.8%) finishes the day markedly lower after announcing earlier that it will delay seeking regulatory approval for migalastat HCI, its experimental Fabry disease drug until the second half of next year. Comment! [Healthcare, On the Move]
-
Monday, June 17, 12:45 PM
Midday top 10 gainers: FRO +24%. KNDI +23%. IGLD +20%. HOTR +17%. LIVE +16%. DQ +15%. BIOL +14%. HAST +14%. GNK +13%. CLFD +13%.
Midday top 10 Losers: FOLD -25%. ORMP -15%. SGOC -12%. EDAP -11%. AXU -10%. BLIN -9%. CERE -9%. RVLT -9%. TEX -9%. PXLW -9%. Comment! [On the Move] -
Monday, June 17, 9:11 AM
Premarket gainers: OSH +47%. FRO +21%. KNDI +16%. LDK +8%. MNKD +5%. AMD +5%. DVAX +5%. NFLX +5%.
Losers: FOLD -29%. TEX -14%. MDVN -7%. Comment! [On the Move] - Monday, June 17, 8:25 AM Amicus Therapeutics (FOLD) falls 25% premarket as the company holds a conference call to discuss the regulatory strategy for its Fabry disease treatment migalastat HCL. FOLD says it plans to incorporate information from three trials in an NDA: Trial 011 (top-line data expected in Q4), trial 012 (top-line data expected in H2 2014), and data from a long-term integrated Phase 2 study. An FDA meeting to discuss Fabry Monotherapy's approval pathway is now expected in H2 2014. (webcast) Comment! [Healthcare, On the Move]
- Thursday, May 9, 5:44 PM Amicus Theraputics (FOLD): Q1 EPS of -$0.35 misses by $0.02. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Tuesday, March 12, 4:27 PM Amicus Theraputics (FOLD): Q4 EPS of -$0.20 beats by $0.17. Shares -1.6% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
- Friday, February 15, 1:48 PM Amicus Therapeutics (FOLD -24.7%) tanks after reporting additional Stage 1 results from the ongoing Phase 3 study of oral migalastat HCl monotherapy in patients with Fabry disease. Initial top-line results previously reported in December, 2012 for the primary endpoint in Stage 1 did not meet statistical significance. The pre-specified primary and secondary analyses of the primary endpoint numerically favored migalastat HCl over placebo, but not enough to allay investor concerns. Comment! [Healthcare, On the Move]
-
Friday, February 15, 1:00 PM
Midday top 10 gainers: URRE +21%. QLIK +18%. VBFC +17%. SAAS +16%. BIOF +15%. MM +12%. ONP +11%. BVX +12%. RBPAA +12%. XRSC +11%.
Midday top 10 losers: LOGM -29%. FOLD -24%. EHTH -22%. CJJD -17%. BOSC -12%. END -11%. ASGN -11%. RKUS -11%. IPGP -10%. WHX -10%. Comment! [On the Move] - Thursday, February 14, 9:40 AM Amicus Therapeutics (FOLD) announces positive Phase II results for its AT2220 treatment for Pompe disease, a genetic disorder that is characterized by progressive skeletal muscle weakness and respiratory insufficiency, and which affects 5,000 to 10,000 people globally. AT2220 was given in combination with enzyme replacement therapy. Amicus' shares +2.1% but down off premarket highs. (PR) Comment! [Healthcare, On the Move]
-
Thursday, January 17, 12:53 PM
Midday top 10 gainers: NEWL +55%. KSWS +48%. SSE +44%. HMNY +21%. CALI +25%. GV +18%. FSI +14%. SHIP +14%. HILL +13%. NLS +13%.
Midday top 10 Losers: HOTR -17%. AMS -13%. PWER -8%. MY -8%. FET -7%. SZYM -8%. CLSN -8%. LEAP -7%. FOLD -7%. MELA -7%. Comment! [On the Move] -
Wednesday, January 16, 5:41 PM
After-hours top gainers, as of 5:15 p.m.: KSWS +57%. CBS +8%. ARQL +5%. FOLD +4%. PLXS +4%.
After-hours top losers: COLM -9%. NTI -4%. HGG -4%. SLM -3%. FET -3%. Comment! [On the Move] - Friday, January 4, 9:24 AM Amicus Therapeutics (FOLD) +10.6% premarket after the biopharma company announces positive preliminary results from all four dose cohorts in a phase 2 study of its treatment for Pompe disease, a lysosomal storage disease characterized by progressive skeletal muscle weakness and respiratory insufficiency. Comment! [Healthcare, On the Move]
-
Friday, January 4, 9:10 AM
Premarket gainers: FOLD +10%. ALU +7%. HNR +6%. GEVA +5%.
Losers: ARAY -29%. Comment! [On the Move] -
Thursday, January 3, 12:45 PM
Midday top 10 gainers: SPWR +38%. VISN +30%. MDCI +20%. FORD +20%. BGMD +19%. TSL +19%. CRDC +19%. FOLD +19%. TELK +18%. JASO +16%.
Midday top 10 Losers: LPH -73%. ALLT -23%. MLNX -14%. FDO -12%. AMPL -12%. TRIT -11%. PKT -10%. SSI -9%. LODE -9%. HPJ -9%. 1 Comment [On the Move] -
Thursday, January 3, 9:10 AM
Premarket gainers: BGMD +22%. SPWR +16%. ALU +10%. CBMX +10%. FOLD +8%. TASR +6%. LDK +6%. ZGNX +5%.
Losers: MLNX -18%. ALLT -10%. FDO -10%. KERX -6%. BIIB -6%. Comment! [On the Move] -
Wednesday, December 26, 2012, 5:57 PM
After-hours top gainers, as of 5:30 p.m.: MACK +5%. CLDX +4%. FOLD +4%. IDIX +3%. NBIX +2%.
After-hours top losers: AMBA -2%. DGAZ -2%. MRVL -2%. DNDN -2%. PRSS -1%. 1 Comment [On the Move]